Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler®
160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on
top of Symbicort® Turbuhaler® 160/4.5 μg 1 inhalation twice a day (bid) in adult asthma
patients.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide, Formoterol Fumarate Drug Combination Terbutaline